Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
54 studies found for:    ebola vaccine
Show Display Options
Rank Status Study
1 Active, not recruiting Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
Condition: Ebola Virus Disease
Interventions: Biological: Ebola Vaccine - low dose;   Biological: Ebola Vaccine - mid dose;   Biological: Ebola Vaccine - high dose;   Biological: Placebo
2 Completed Evaluating an Ebola and a Marburg Vaccine in Uganda
Conditions: Ebola Virus Disease;   Marburg Virus Disease
Interventions: Biological: Ebola vaccine;   Biological: Marburg vaccine;   Other: Placebo injection
3 Active, not recruiting Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Condition: Ebola Virus
Interventions: Biological: VSVG-ZEBOV;   Biological: ChAd3-EBO Z;   Drug: Placebo
4 Active, not recruiting Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: cAd3-EBOZ;   Biological: cAd3-EBO;   Biological: MVA-EbolaZ
5 Completed Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Condition: Ebola Viruses
Interventions: Other: Placebo;   Biological: BPSC-1001 Vaccine
6 Active, not recruiting Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)
Condition: Prevention of Ebola Infection
Interventions: Biological: V920 Consistency Lot A;   Biological: V920 Consistency Lot B;   Biological: V920 Consistency Lot C;   Biological: V920 High-dose Lot;   Biological: Placebo to V920
7 Completed Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine
Condition: Ebola Viruses
Interventions: Biological: BPSC-1001 (VSVΔG-ZEBOV);   Other: Placebo
8 Completed Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Condition: Ebola Virus
Interventions: Biological: BPSC-1001 Vaccine;   Other: Placebo
9 Active, not recruiting A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.
Condition: Ebola Virus Disease
Intervention: Biological: VSV-ZEBOV
10 Recruiting Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo
11 Active, not recruiting VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults
Condition: Healthy Adult Immune Responses to Vaccine
Interventions: Biological: VRC-EBOMVA079-00-VP (MVA-EbolaZ);   Biological: VRC-EBOADC069-00-VP (cAd3-EBO)
12 Completed Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)
Condition: Hemorrhagic Fever, Ebola
Intervention: Biological: rVSVΔ-ZEBOV-GP
13 Completed Ebola and Marburg Virus Vaccines
Conditions: Ebola Vaccines;   Marburg Virus Disease;   Ebola Virus Disease;   Marburgvirus;   Ebolavirus
Interventions: Drug: VRC-EBODNA023-00-VP;   Drug: VRC-MARDNA025-00-VP
14 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo
15 Completed Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
Condition: Ebola Virus Disease
Interventions: Biological: ChAd3-EBO Z;   Biological: MVA-EBO Z
16 Recruiting Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
17 Active, not recruiting A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV
Condition: Ebola Virus Disease
Interventions: Biological: ChAd3-EBO-Z;   Biological: Ad26.ZEBOV
18 Active, not recruiting A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z
Condition: Ebola Virus Disease
Interventions: Biological: MVA-EBO Z;   Biological: ChAd3-EBO Z
19 Completed A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.
Condition: Ebola Virus Disease
Intervention: Biological: Ad5-EBOV
20 Active, not recruiting Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults
Condition: Hemorrhagic Fever, Ebola
Intervention: Biological: HPIV3-EbovZ GP Vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years